Clinical Trials Logo

T-lymphoblastic Lymphoma clinical trials

View clinical trials related to T-lymphoblastic Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06376721 Recruiting - Clinical trials for T-lymphoblastic Lymphoma

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Start date: April 14, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment.

NCT ID: NCT06136364 Recruiting - Clinical trials for T-lymphoblastic Lymphoma

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Start date: August 15, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.

NCT ID: NCT05576532 Recruiting - Safety Clinical Trials

Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

Start date: January 10, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Venetoclax plus IM2 regimen for relapsed and refractory T lymphoblastic lymphoma/leukemia. Dosage of Venetoclax:100mg/d-400mg/d(dose adjustment when concomitant used with CYP3A inhibitor) for 1-28 days (at least 7 days); IM2 regimen: Ifosfamide 1-1.5g/m2/d for 5 days; Mitoxantrone 6-8g/m2/d for 3 days( or Liposome mitoxantrone 20mg/m2 d1 or Idarubicin 6-8mg/m2/d for 3 days) ;methotrexate 1-1.5g/m2/d for 1 day;

NCT ID: NCT04620655 Recruiting - Clinical trials for T Acute Lymphoblastic Leukemia

RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

Start date: November 15, 2020
Phase: N/A
Study type: Interventional

This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.

NCT ID: NCT04582487 Recruiting - Clinical trials for T Acute Lymphoblastic Leukemia

Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL

Start date: May 19, 2021
Phase: N/A
Study type: Interventional

This is a biological study for R/R T-ALL/LBL or ETP-ALL patients. Bone marrow and/or peripheral blood samples will be subjected to genomic, DSRP profiling and phosphoproteomic screening to identify novel potential therapeutic approach and thus, eligibility for treatment based on molecular and DSRP data. As soon as genomic and DSRP profiling are made available, local Investigator can submit to local ethic committee a request for clinical use of identified compound.

NCT ID: NCT04004637 Recruiting - Clinical trials for Acute Lymphocytic Leukemia

CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia

Start date: August 25, 2019
Phase: Phase 1
Study type: Interventional

This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute Lymphocytic Leukemia. And to evaluate the pharmacokinetics of CD7 CAR-T cells in patients.

NCT ID: NCT03558412 Recruiting - Clinical trials for T-lymphoblastic Lymphoma

A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

To explore the safety, tolerability, and clinical effects of decitabine combined with Second-line chemotherapy regimens for patients with relapsed or refractory T-lymphoblastic lymphoma.

NCT ID: NCT00501826 Recruiting - Clinical trials for T Acute Lymphoblastic Leukemia

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Start date: July 11, 2007
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.